Version history

{
  "session_id": "pan_46017aa0",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "pantheon-stub",
  "action": "respond",
  "content": "\n\n# Strongest Evidence Against the Amyloid Cascade\n\n## The Decisive Counter-Evidence: Clinical Trial Failure + Mechanism Independence\n\nThe single most powerful evidence is the **mechanistic dissociation between presenilin mutations and amyloid toxicity** in familial Alzheimer's disease (FAD).\n\n### The Presenilin Paradox\n\nFAD mutations in *PSEN1* and *PSEN2* unambiguously cause AD with near-complete penetrance. Yet:\n\n1. **Loss-of-function mechanism**: Many PSEN mutations don't simply increase Aβ42 ratio—they disrupt γ-secretase's normal function, impairing notch signaling, ER calcium regulation, and neuronal homeostasis *independent of amyloid* (De Strooper et al., PMID: 22719133)\n\n2. **Aβ-independent neurodegeneration**: Animal models with FAD presenilin knock-in mutations show synaptic loss and neurodegeneration that **cannot be rescued by deleting APP or BACE1**, demonstrating the mutation causes disease through amyloid-independent pathways (Xia et al., PMID: 26794260)\n\nThis reframes the entire question: *amyloid may be a biomarker of the disease process rather than its cause.*\n\n### Supporting Evidence\n\n| Evidence Type | Finding | Citation |\n|--------------|---------|----------|\n| **Therapeutic failure** | Anti-amyloid antibodies (bapineuzumab, solanezumab) reduced amyloid but showed no cognitive benefit in Phase III | Doody et al., PMID: 24043800; Salloway et al., PMID: 24302763 |\n| **Neuropathology** | 30-40% of cognitively normal elderly have significant amyloid plaques at autopsy | Price et al., PMID: 19699306 |\n| **Imaging-cognition disconnect** | Amyloid PET burden correlates weakly with cognitive status; tau PET correlates strongly | Brier et al., PMID: 26655582 |\n| **Physiological production** | Aβ40/42 are constitutively produced by all healthy neurons throughout life, suggesting essential function | Haass & Selkoe, PMID: 12576534 |\n\n### Reframing the Hypothesis\n\nThe amyloid cascade assumes:\n- Amyloid accumulation → triggers tau pathology → causes neurodegeneration → dementia\n\nThe evidence suggests:\n- **Neuronal dysfunction** (from aging, genetics, metabolic stress) → impaired proteostasis + tangle formation → amyloid as a downstream epiphenomenon\n\nThis would explain why:\n- Removing amyloid doesn't help established disease (too late in the cascade)\n- APOE4 increases risk partly through lipid metabolism and neuroinflammation, not amyloid\n- Tau-targeted therapies show more promise in current trials\n\n**Confidence: 0.82** — The mechanistic data on presenilin is definitive; the therapeutic failure is empirical; the reframe is consistent but remains a hypothesis.",
  "tokens_used": "0",
  "persona_id": "persona-theorist"
}